These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 38005991)
1. COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation-A Single-Center Study. Souan L; Abdel-Razeq H; Nashwan S; Al Badr S; Alrabi K; Sughayer MA Vaccines (Basel); 2023 Oct; 11(11):. PubMed ID: 38005991 [TBL] [Abstract][Full Text] [Related]
2. Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2. Szabó E; Modok S; Rónaszéki B; Faragó A; Gémes N; Nagy LI; Hackler L; Farkas K; Neuperger P; Balog JÁ; Balog A; Puskás LG; Szebeni GJ Front Med (Lausanne); 2023; 10():1176168. PubMed ID: 37529238 [TBL] [Abstract][Full Text] [Related]
3. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612 [TBL] [Abstract][Full Text] [Related]
4. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy. Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288 [TBL] [Abstract][Full Text] [Related]
6. Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population. Aijaz J; Hussain S; Naseer F; Kanani F; Anis S; Sarfaraz S; Saeed S; Farooq H; Jamal S Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632448 [TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial. Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC; Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958 [TBL] [Abstract][Full Text] [Related]
8. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2. Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231 [TBL] [Abstract][Full Text] [Related]
9. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel. Park S; Gatchalian KK; Oh H Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010 [TBL] [Abstract][Full Text] [Related]
10. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy). Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E; Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961 [TBL] [Abstract][Full Text] [Related]
11. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan. Matsuura T; Fukushima W; Nakagama Y; Kido Y; Kase T; Kondo K; Kaku N; Matsumoto K; Suita A; Komiya E; Mukai E; Nitahara Y; Konishi A; Kasamatsu A; Nakagami-Yamaguchi E; Ohfuji S; Kaneko Y; Kaneko A; Kakeya H; Hirota Y Vaccine; 2022 Sep; 40(38):5631-5640. PubMed ID: 36028457 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine. Rákóczi É; Magócs G; Kovács S; Nagy B; Szűcs G; Szekanecz Z Diagnostics (Basel); 2023 Feb; 13(3):. PubMed ID: 36766663 [TBL] [Abstract][Full Text] [Related]
13. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination. Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W Front Immunol; 2022; 13():967051. PubMed ID: 36159863 [TBL] [Abstract][Full Text] [Related]
14. Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients. Souan L; Abdel-Razeq H; Al Zughbieh M; Al Badr S; Sughayer MA Viruses; 2023 Jun; 15(7):. PubMed ID: 37515127 [TBL] [Abstract][Full Text] [Related]
15. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
16. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization. Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830 [TBL] [Abstract][Full Text] [Related]
17. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals. Hayer J; Urlaub E Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594 [TBL] [Abstract][Full Text] [Related]
19. Variation in antibody titers determined by Abbott and Roche Elecsys SARS-CoV-2 assays in vaccinated healthcare workers. Nakai M; Yokoyama D; Sato T; Sato R; Kojima C; Shimosawa T Heliyon; 2023 Jun; 9(6):e16547. PubMed ID: 37235203 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Anti-SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine. Carta M; Marinello I; Cappelletti A; Rodolfi A; Cerrito E; Bernasconi C; Gottardo M; Dal Lago F; Rizzetto D; Barzon E; Giavarina D Am J Clin Pathol; 2022 Feb; 157(2):212-218. PubMed ID: 34463321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]